Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
New Approval, Clinical Trial for YM Biosciences’ Cancer Drug
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
